Opening of the Paris site, Pitié-Salpêtrière, on 21 June 2021

Randomised, open-label, multi-site phase II clinical trial in newly diagnosed glioblastoma treated with surgery, concomitant temoradiation and adjuvant temozolomide +/- ultrasound-induced blood-brain barrier opening.

More about the study